• Molecular NameMivacurium
  • SynonymNA
  • Weight1029.28
  • Drugbank_IDDB01226
  • ACS_NO106791-40-6
  • Show 3D model
  • LogP (experiment)0.015
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It is an antagonist of nicotinic neuromuscular acetylcholine receptors.
  • Absorption_value0.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein bindingN/A
  • Volume of distribution (VD)Drug in general, 0.2 L/kg. Trans–trans isomer, 0.047 L/kg; cis–trans isomer, 0.054 L/kg; cis–cis isomer, 0.189 L/kg.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.
  • Half lifeTrans–trans isomer, 2.4 min; cis–trans isomer, 2.0 min; cis–cis isomer, 28.5 min (mean values).
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOverdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A